Aetna's CEO envisions CVS deal helping it lead the way on social determinants of health (SDOH); the Senate health chair releases 2 draft bills on opioids; the medical community criticizes former Senator Rick Santorum, R-Pennsylvania, for suggesting student activitists learn CPR instead of advocating for gun control.
In an interview with The Washington Post, Aetna’s chief executive said its merger with CVS could allow it to act as a neighborhood gateway focusing more on the social determinants of health (SDOH). Mark T. Bertolini said the $69 billion deal could lead to a future where pharmacists or medical professionals could assist with appointments or focus on nonmedical support, such as coordinating rides, meal assistance, nutrition counseling, or social supports.
Senate Health Committee Chairman Lamar Alexander, R-Tennessee, released 2 draft bills aimed at curbing the overprescribing of opioids and stopping fentanyl, a synthetic opioid, at the border, The Hill reported. One bill would let the FDA require drug manufacturers to package certain opioids in blister packs, making it easier for a doctor to write a smaller quantity. The other bill would ensure the FDA can spend the $94 million included in the omnibus bill passed last week to boost laboratory capabilities and upgrade other methods to combat fentanyl.
Healthcare professionals, especially surgeons who have operated on gunshot victims, criticized former Senator Rick Santorum, R-Pennsylvania, after he suggested that student activists should learn CPR instead of protesting for gun control. Doctors took to Twitter to share their opinions and also in magazines sharing their experiences operating on children and young adults, like a Tenessee surgeon, Eugene Gu, MD, who penned an article in Tuesday's Newsweek.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More